SCHEMBL14945752

SCHEMBL14945752

Cc1ccc(COCC(=O)C(C)C)cc1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 4/20 0.47
NPC1 O15118 2/20 0.47
MAOB P27338 2/20 0.42
AGXT P21549 2/20 0.42
PARP10 Q53GL7 1/20 0.41
KCNH2 Q12809 1/20 0.41
CA1 P00915 1/20 0.41
CA2 P00918 1/20 0.41
CA9 Q16790 1/20 0.41
LMNA P02545 1/20 0.40
POLB P06746 1/20 0.40
CYP1A2 P05177 1/20 0.40
CYP2C19 P33261 1/20 0.40
HPGD P15428 1/20 0.40
ALDH1A1 P00352 2/20 0.40
MAPT P10636 1/20 0.40
MAPK1 P28482 1/20 0.40
CTBP2 P56545 1/20 0.39
MMP1 P03956 1/20 0.38
MMP2 P08253 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10165853 0.84 TSHR (0.50) RAB9ANPC1CA1CA2CA9
SCHEMBL14935708 0.83 CA1 (0.50) RAB9ANPC1AGXTCA1CA2
SCHEMBL14945750 0.83 RAB9A (0.41) RAB9ANPC1MAOBAGXTPARP10
SCHEMBL13886095 0.79 RAB9A (0.51) RAB9ANPC1MAOBAGXTPARP10
SCHEMBL10305879 0.79 RAB9A (0.51) RAB9ANPC1MAOBAGXTPARP10
SCHEMBL19598480 0.79 PPARG (0.48) ALDH1A1
SCHEMBL7221565 0.78 RAB9A (0.50) RAB9ANPC1MAOBAGXTPARP10
SCHEMBL21664684 0.78 RAB9A (0.54) RAB9ANPC1MAOBAGXTPARP10
SCHEMBL21393011 0.78 RXRA (0.50) RAB9ANPC1POLBALDH1A1
SCHEMBL25623263 0.77 IDO1 (0.46) RAB9ANPC1LMNAPOLBHPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8492556-B2 2,5-Dioxoimidazolidin-1-yl-3-phenylurea derivatives as formyl peptide receptor like-1 (FPRL-1) receptor modulators ALLERGAN, INC. (US) 2013-07-23 US disclosed
US-20130123215-A1 2,5-DIOXOIMIDAZOLIDIN-1-YL-3-PHENYLUREA DERIVATIVES AS FORMYL PEPTIDE RECEPTOR LIKE-1 (FPRL-1) RECEPTOR MODULATORS ALLERGAN, INC. (US) 2013-05-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130123215-A1 2,5-DIOXOIMIDAZOLIDIN-1-YL-3-PHENYLUREA DERIVATIVES AS FORMYL PEPTIDE RECEPTOR LIKE-1 (FPRL-1) RECEPTOR MODULATORS FPR1, FPR2, FPR3 RAB9A 4597/4885NPC1 2108/4885MAOB 1599/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.